Bioventus/$BVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bioventus
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Ticker
$BVS
Sector
Primary listing
Employees
930
Headquarters
Website
Bioventus Metrics
BasicAdvanced
$598M
26.88
$0.33
0.72
-
Price and volume
Market cap
$598M
Beta
0.72
52-week high
$10.13
52-week low
$5.81
Average daily volume
347K
Financial strength
Current ratio
1.701
Quick ratio
1.119
Long term debt to equity
127.879
Total debt to equity
136.288
Interest coverage (TTM)
2.13%
Profitability
EBITDA (TTM)
77.641
Gross margin (TTM)
68.33%
Net profit margin (TTM)
4.00%
Operating margin (TTM)
9.92%
Effective tax rate (TTM)
-6.09%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
4.99%
Return on equity (TTM)
13.17%
Valuation
Price to earnings (TTM)
26.879
Price to revenue (TTM)
1.04
Price to book
3.23
Price to tangible book (TTM)
-3.1
Price to free cash flow (TTM)
8.195
Free cash flow yield (TTM)
12.20%
Free cash flow per share (TTM)
1.082
Growth
Revenue change (TTM)
-0.91%
Earnings per share change (TTM)
-158.93%
3-year revenue growth (CAGR)
3.52%
10-year revenue growth (CAGR)
8.40%
3-year earnings per share growth (CAGR)
-49.65%
10-year earnings per share growth (CAGR)
-27.09%
What the Analysts think about Bioventus
Analyst ratings (Buy, Hold, Sell) for Bioventus stock.
Bioventus Financial Performance
Revenues and expenses
Bioventus Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bioventus stock?
Bioventus (BVS) has a market cap of $598M as of March 17, 2026.
What is the P/E ratio for Bioventus stock?
The price to earnings (P/E) ratio for Bioventus (BVS) stock is 26.88 as of March 17, 2026.
Does Bioventus stock pay dividends?
No, Bioventus (BVS) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Bioventus dividend payment date?
Bioventus (BVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Bioventus?
Bioventus (BVS) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.